PMID- 37582497
OWN - NLM
STAT- MEDLINE
DCOM- 20230817
LR  - 20230823
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Print)
IS  - 1011-8934 (Linking)
VI  - 38
IP  - 32
DP  - 2023 Aug 14
TI  - Effects of COVID-19 and Influenza Vaccination on Rheumatic Diseases: Results From 
      a Survey of Patient-Reported Outcomes After Vaccination.
PG  - e247
LID - 10.3346/jkms.2023.38.e247 [doi]
LID - e247
AB  - BACKGROUND: This study aimed to compare the occurrence of adverse events (AEs) 
      and disease flares after vaccination against coronavirus disease 2019 (COVID-19) 
      and influenza in patients with autoimmune rheumatic diseases (ARDs). METHODS: 
      Between November 2021 and March 2022, a survey was conducted among patients with 
      ARD who received COVID-19 and influenza vaccinations. The questionnaire included 
      11 mandatory and closed-ended questions, and the following items were collected: 
      medical history, immunization history, type of vaccine, patient-reported AEs, 
      flare-up of the underlying disease after vaccination, and a confirmed diagnosis 
      of COVID-19 or influenza. We compared the occurrence of vaccine-related adverse 
      reactions to the COVID-19 and influenza vaccines based on the survey results. 
      Multivariate logistic regression analysis was used to identify the factors 
      affecting AEs or disease flares and to compare the post-vaccine response to mixed 
      and matched vaccines. RESULTS: We analyzed 601 adults with ARD who received the 
      COVID-19 vaccine, with a mean age of 49.6 years (80.5% female). A total of 255 
      participants (42.4%) received a complete course of primary vaccination, 342 
      (56.9%) completed the booster dose, and 132 (38.6%) received a mixed vaccine. The 
      frequencies of AEs (188 [52.2%] vs. 21 [5.8%]; P < 0.001) and disease flares (58 
      [16.2%] vs. 5 [1.4%]; P < 0.001) after COVID-19 vaccination were significantly 
      higher than those after influenza vaccination. In the risk factor analysis, 
      previous allergic reaction to other vaccines (odds ratio, 1.95; confidence 
      interval, 1.07-3.70; P = 0.034) was the only factor associated with the 
      occurrence of AEs. There was no difference in the post-vaccine responses between 
      the mixed and matched vaccines. CONCLUSION: The results of the survey of patients 
      with ARD revealed that patient-reported AEs and underlying disease flares after 
      receiving the COVID-19 vaccine were significantly higher than those after the 
      influenza vaccine.
CI  - (c) 2023 The Korean Academy of Medical Sciences.
FAU - Kim, Ji-Won
AU  - Kim JW
AUID- ORCID: 0000-0002-2827-0884
AD  - Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea.
FAU - Jung, Ju-Yang
AU  - Jung JY
AUID- ORCID: 0000-0001-7313-0795
AD  - Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea.
FAU - Suh, Chang-Hee
AU  - Suh CH
AUID- ORCID: 0000-0001-6156-393X
AD  - Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea.
FAU - Ye, Young-Min
AU  - Ye YM
AUID- ORCID: 0000-0002-7517-1715
AD  - Department of Allergy & Clinical Immunology, Ajou University School of Medicine, 
      Suwon, Korea.
FAU - Kim, Hyoun-Ah
AU  - Kim HA
AUID- ORCID: 0000-0003-2609-3367
AD  - Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea. 
      nakhada@naver.com.
LA  - eng
PT  - Journal Article
DEP - 20230814
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Influenza Vaccines)
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *COVID-19/prevention & control
MH  - *COVID-19 Vaccines/adverse effects
MH  - *Influenza Vaccines/adverse effects
MH  - *Influenza, Human/prevention & control
MH  - Patient Reported Outcome Measures
MH  - *Rheumatic Diseases/complications
MH  - Surveys and Questionnaires
MH  - Vaccination/adverse effects/methods
PMC - PMC10427213
OTO - NOTNLM
OT  - Adverse Events
OT  - COVID-19 Vaccine
OT  - Influenza Vaccine
OT  - Surveys and Questionnaires
OT  - Underlying Rheumatic Diseases Flare Up
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2023/08/16 00:42
MHDA- 2023/08/17 06:42
PMCR- 2023/08/14
CRDT- 2023/08/15 19:43
PHST- 2023/03/14 00:00 [received]
PHST- 2023/04/05 00:00 [accepted]
PHST- 2023/08/17 06:42 [medline]
PHST- 2023/08/16 00:42 [pubmed]
PHST- 2023/08/15 19:43 [entrez]
PHST- 2023/08/14 00:00 [pmc-release]
AID - 38.e247 [pii]
AID - 10.3346/jkms.2023.38.e247 [doi]
PST - epublish
SO  - J Korean Med Sci. 2023 Aug 14;38(32):e247. doi: 10.3346/jkms.2023.38.e247.